ClinicalTrials.gg

Program

enzalutamide

Also written as “Enzalutamide”, “MDV3100” and “HC-1119”.

Its studies are mostly in Prostatic Neoplasms · Neoplasms · Breast Neoplasms · Prostatic Neoplasms, Castration-Resistant · Neoplasm Metastasis, led by 6 companies.

Furthest: phase 4, since Oct 31, 201354 company-led studies, 7 open or runningNext primary completion: Apr 30, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Astellas Pharma313 open or runningphase 4since Oct 31, 2013Jan 18, 2011Apr 30, 2027phase 1 · NCT07783282
Pfizer162 open or runningphase 4since Nov 18, 2013Jul 31, 2007none ahead
Hinova Pharmaceuticals41 open or runningphase 3since Feb 17, 2019Dec 11, 2018none ahead
Alessa Therapeutics11 open or runningphase 1since Dec 14, 2023Dec 14, 2023Dec 30, 2028phase 1 · NCT06257693
Applied Biology10 open or runningphase 3since Jul 28, 2021Jul 28, 2021none ahead
hinova-pharmaceuticals-usa-inc10 open or runningphase 3since Feb 20, 2019Feb 20, 2019none ahead

Also a collaborator on its studies: Exelixis, Novartis, clovis-oncology-inc, Johnson & Johnson, medivation-llc-a-wholly-owned-subsidiary-of-pfizer-inc and Gilead Sciences.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 38 studies since Jul 31, 2007.

  1. Feb 29, 2016Phase 2 study in Prostatic NeoplasmsAstellas Pharma · NCT02799745 · 227 enrolled · United States, Canada
  2. Sep 7, 2016Phase 3 study in Breast NeoplasmsPfizer · NCT02929576 · United States
  3. Sep 27, 2016Phase 4 study in Prostatic NeoplasmsAstellas Pharma · NCT02918968 · 206 enrolled · Japan
  4. Nov 7, 2016Phase 2 study in Prostatic NeoplasmsAstellas Pharma · NCT02960022 · 900 enrolled · United States, Argentina, Australia and more
  5. Aug 20, 2018Phase 4 study in Metastatic Castration Resistant Prostate CancerAstellas Pharma · NCT03641560 · 52 enrolled · India
  6. Dec 11, 2018Hinova Pharmaceuticals's first studies: 3 phase 1 studies in Metastatic Castration Resistant Prostate CancerNew to Hinova PharmaceuticalsHinova Pharmaceuticals · NCT03778047, NCT03776968, NCT03774056
  7. Feb 17, 2019Phase 3 study in MCRPCHinova Pharmaceuticals · NCT03851640 · 417 planned · China
  8. Feb 20, 2019hinova-pharmaceuticals-usa-inc's first study: phase 3 study in Prostate Cancer MetastaticNew to hinova-pharmaceuticals-usa-inchinova-pharmaceuticals-usa-inc · NCT03850795 · 104 enrolled · United States, Australia, Austria and more
  9. Aug 19, 2019Phase 3 study in Metastatic Hormone Sensitive Prostate CancerAstellas Pharma · NCT04076059 · 180 enrolled · China
  10. Sep 17, 2019Phase 1 study in Prostatic NeoplasmsAstellas Pharma · NCT04094519 · 24 enrolled · Moldova, Republic of
  11. Mar 25, 2021Phase 3 study in Prostatic NeoplasmsPfizer · NCT04821622 · 599 enrolled · United States, Argentina, Australia and more
  12. Jul 28, 2021Applied Biology's first study: phase 3 study in COVID-19 Respiratory InfectionNew to Applied BiologyApplied Biology · NCT04986176 · 602 enrolled
  13. Dec 14, 2023Alessa Therapeutics's first study: phase 1 study in Prostate AdenocarcinomaNew to Alessa TherapeuticsAlessa Therapeutics · NCT06257693 · 45 planned · United States
  14. Aug 20, 2026Phase 1 study in Prostatic NeoplasmsAstellas Pharma · NCT07783282 · 56 planned · Bulgaria

Ahead

  1. Apr 30, 2027Primary completion: phase 1 study in Prostatic NeoplasmsAstellas Pharma · NCT07783282
  2. Dec 30, 2028Primary completion: phase 1 study in Prostate AdenocarcinomaAlessa Therapeutics · NCT06257693
  3. Jul 31, 2029Primary completion: phase 2 study in Prostatic NeoplasmsAstellas Pharma · NCT02960022

TargetBeta

AR →read by rule
“A deuterated form of enzalutamide, an orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) ”NCIt, by rule
“Androgen Receptor antagonist”ChEMBL 37, by rule

Other programs on AR

ProgramCompanyFurthest phaseStudies
apalutamideruleJohnson & Johnsonphase 431
darolutamideruleBayerphase 426
Clascoteronerulecassiopea-spaphase 419
ostarinerulegtxphase 315
rezvilutamideruleJiangsu HengRui Medicinephase 313
dezandrodegruleBristol-Myers Squibbphase 35
Cyproterone AcetateruleEurofarma Laboratoriosphase 34
Androgen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0915Johnson & Johnsonphase 33
HRS-5041Jiangsu HengRui Medicinephase 26
luxdegalutamideNovartisphase 23
luxdegalutamideNovartisphase 22
Androgen Receptor Degrader AZD9750ruleAstraZenecaphase 21

Studies

All 54 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07783282Prostatic Neoplasms · Bulgaria1RecruitingAstellas PharmaApr 30, 202756
NCT06257693Prostate Adenocarcinoma · United States1RecruitingAlessa TherapeuticsDec 30, 202845
NCT04986176COVID-19 Respiratory Infection3UNKNOWNApplied BiologyDec 31, 2022602
NCT04821622Prostatic Neoplasms · United States, Argentina, Australia and more3Active, not recruitingPfizerFeb 18, 2026599
NCT04094519Prostatic Neoplasms · Moldova, Republic of1CompletedAstellas PharmaDec 27, 202024
NCT04076059Metastatic Hormone Sensitive Prostate Cancer · China3Active, not recruitingAstellas PharmaNov 18, 2022180
NCT03850795Prostate Cancer Metastatic · United States, Australia, Austria and more3Terminatedhinova-pharmaceuticals-usa-incJun 28, 2024104
NCT03851640MCRPC · China3RecruitingHinova PharmaceuticalsSep 2025417
NCT03778047Metastatic Castration Resistant Prostate Cancer · China1CompletedHinova PharmaceuticalsOct 24, 201810
NCT03776968Metastatic Castration Resistant Prostate Cancer · China1CompletedHinova PharmaceuticalsJan 15, 201847
NCT03774056Metastatic Castration Resistant Prostate Cancer · China1CompletedHinova PharmaceuticalsSep 26, 201843
NCT03641560Metastatic Castration Resistant Prostate Cancer · India4CompletedAstellas PharmaFeb 20, 202452
NCT02960022Prostatic Neoplasms · United States, Argentina, Australia and more2Active, not recruitingAstellas PharmaJul 31, 2029900
NCT02918968Prostatic Neoplasms · Japan4CompletedAstellas PharmaMar 27, 2020206
NCT02929576Breast Neoplasms · United States3WithdrawnPfizerApr 20190
NCT02799745Prostatic Neoplasms · United States, Canada2CompletedAstellas PharmaAug 28, 2020227
NCT02677896Metastatic Hormone Sensitive Prostate Cancer · United States, Argentina, Australia and more3CompletedAstellas PharmaOct 14, 20181,150
NCT02528643Advanced Hepatocellular Carcinoma · United States, Canada, Hong Kong and more2CompletedAstellas PharmaOct 2, 2017165
NCT02441517Neoplasm Metastasis · United States4TerminatedAstellas PharmaMar 15, 20174
NCT02384382Prostatic Neoplasms · United States2CompletedPfizerMay 3, 201923
NCT02319837Prostatic Neoplasms · United States, Australia, Austria and more3Active, not recruitingPfizerJan 31, 20231,068
NCT02294461Bulbo-Spinal Atrophy, X-Linked · China, Hong Kong, South Korea and more3CompletedAstellas PharmaSep 20, 2015395
NCT02288247Neoplasm Metastasis · Austria, Belgium, Czechia and more3CompletedAstellas PharmaApr 30, 2020688
NCT02225093Prostatic Neoplasms · Moldova, Republic of1CompletedAstellas PharmaFeb 3, 201412
NCT02138799Drug-Drug Interaction (DDI) · Germany1CompletedAstellas PharmaSep 201328
NCT02138162Severe Hepatic Impairment · Bulgaria1CompletedAstellas PharmaMar 201416
NCT02124668Prostatic Neoplasms · Georgia, Russian Federation2CompletedAstellas PharmaMay 25, 201730
NCT02116582Metastatic Castration-Resistant Prostate Cancer · Belgium, France, Germany and more4CompletedAstellas PharmaMay 8, 2016215
NCT02091960Breast Neoplasms · United States, Belgium, Canada and more2CompletedAstellas PharmaFeb 28, 2017103
NCT02007512Breast Neoplasms · United States, Belgium, Canada and more2CompletedPfizerSep 23, 2016247
NCT02003924Prostatic Neoplasms · United States, Argentina, Australia and more3CompletedPfizerJun 28, 20171,401
NCT01995513Prostatic Neoplasms · United States, Australia, Belgium and more4CompletedPfizerNov 15, 2016509
NCT01977651Seizures · United States, Argentina, Australia and more4CompletedAstellas PharmaFeb 1, 2016424
NCT01913379Healthy Subjects · France1CompletedAstellas PharmaDec 201141
NCT01911741Healthy Subjects · Germany1CompletedAstellas PharmaMar 201355
NCT01911728Pharmacokinetics of MDV3100 · South Africa1CompletedAstellas PharmaFeb 21, 201214
NCT01911715Healthy Subjects · Netherlands1CompletedAstellas PharmaJul 20116
NCT01902251Prostatic Neoplasms · United States1CompletedAstellas PharmaOct 201327
NCT01889238Breast Neoplasms · United States, Belgium, Canada and more2CompletedPfizerMar 1, 2015118
NCT01901133Kidney Diseases · Moldova, Republic of1CompletedAstellas PharmaJan 201233
NCT01664923Prostatic Neoplasms · United States2CompletedPfizerFeb 2015396
NCT01663415Neoplasms2WithdrawnAstellas PharmaOct 20140
NCT01650194Neoplasms · United States2CompletedAstellas PharmaJan 4, 201860
NCT01597193Breast Neoplasms · United States1CompletedPfizerDec 15, 2015101
NCT01547299Prostatic Neoplasms · United States, Canada2CompletedPfizerNov 30, 201352
NCT01565928Prostatic Neoplasms · United States1CompletedPfizerJul 1, 201323
NCT01534052Prostatic Neoplasms · United States, Moldova, Republic of, South Africa2CompletedAstellas PharmaApr 18, 201752
NCT01302041Prostatic Neoplasms · Belgium, Czechia, Denmark and more2CompletedAstellas PharmaJul 29, 201267
NCT01288911Prostatic Neoplasms · United States, Belgium, Canada and more2CompletedAstellas PharmaOct 19, 2014375
NCT01284920Prostatic Neoplasms · Japan2CompletedAstellas PharmaJul 12, 201247
NCT01212991Prostatic Neoplasms · United States, Australia, Austria and more3CompletedPfizerSep 30, 20131,717
NCT01091103Metastatic Progressive Castration-resistant Prostate Cancer · United States2CompletedPfizerFeb 29, 201260
NCT00974311Prostatic Neoplasms · United States, Argentina, Australia and more3CompletedPfizerSep 15, 20111,199
NCT00510718Prostatic Neoplasms · United States1CompletedPfizerDec 8, 2008140

How it is read

Names in the registry

  • “Enzalutamide”, 40 entries
  • “enzalutamide”, 13 entries
  • “MDV3100”, 8 entries
  • “HC-1119”, 4 entries
  • “HC1119”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.